A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)

Bristol-Myers Squibb (BMS)

Status: Enrolling

Conditions: Mesothelioma, Malignant

Study type: Observational

Funder types: Industry

Identifiers

NCT05324436

CA209-6AF

Details and patient eligibility

About

The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).

Enrollment: 50 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Initiated treatment with Yervoy and Opdivo in combination for the first time in accordance with the Japanese package insert

Exclusion criteria

• Received combination therapy with Yervoy and Opdivo for indications other than Malignant Pleural Mesothelioma (MPM).
• Received the Yervoy and Opdivo combination for MPM, but for an indication that is outside of the Japanese package insert.

Trial design

50 participants in 1 patient group

Cohort 1

Description:

Participants with unresectable advanced/recurrent malignant pleural mesothelioma (MPM)